Bridging Pharmacokinetics and Pharmacodynamics: A PBPK / PD Model‐Based Approach for Deferasirox Dosing in Transfusion‐Dependent Thalassemia
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Watchara Sakares und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Deferasirox, Thalassemia, Iron Chelating Agents, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Second Century Fund (C2F), Chulalongkorn University, Faculty of Pharmaceutical Sciences Fund Chulalongkorn University, National Research Council of Thailand.
Abstract (Originalsprache)
Patients with transfusion‐dependent thalassemia (TDT) require lifelong blood transfusions, resulting in excessive iron accumulation and necessitating effective chelation therapy. Deferasirox (DFX) is the primary oral iron chelator for managing iron overload; however, the response to this treatment varies substantially within different individuals, potentially because of differences in its pharmacokinetics (PK) and pharmacodynamics (PD). This study aimed to develop a physiologically based pharmacokinetic–pharmacodynamic (PBPK/PD) DFX model, integrating hepatic‐ and transfusion‐derived iron burdens to assess their impact on DFX PK and optimize dosing. The model was developed using clinical PK data from Caucasian and Thai populations, comprising healthy individuals and patients with TDT. TDT‐specific physiological parameters were incorporated into the TDT model. The verified model was applied to predict the targeted DFX dose required to achieve a 25% reduction in the liver iron concentration (LIC) from baseline after 6 months of treatment based on the baseline LIC and blood transfusion regimen. The model demonstrated high predictive accuracy across populations, identifying the effects of iron levels on DFX clearance. Simulations revealed that patients with higher baseline LIC were more likely to achieve the targeted reduction, whereas those with lower LIC required higher doses because of slower iron mobilization. A reduced blood transfusion regimen was associated with improved therapeutic outcomes at the same DFX dose. The PBPK/PD model proposed targeted DFX doses to achieve a 25% reduction based on baseline LIC levels and transfusion regimen, emphasizing the requirement for individualized dosing strategies based on iron burden and blood transfusion patterns to maximize clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
- Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR), Chulalongkorn University, Bangkok, Thailand.
- Certara Predictive Technologies Division, Certara UK Limited, Sheffield, UK.
- Siriraj Thalassemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Division of Hematology/Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Siriraj Genomics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Watchara Sakares, Udomsak Udomnilobol, Xian Pan, Kittika Yampayon, Supachai Ekwattanakit, Vip Viprakasit, Chanin Limwongse, Somdet Srichairatanakool, Polsak Teerawonganan, Vipada Khaowroongrueng, Thomayant Prueksaritanont, Varalee Yodsurang
Förderung
- the Second Century Fund (C2F), Chulalongkorn University
- Faculty of Pharmaceutical Sciences Fund Chulalongkorn University
- National Research Council of Thailand
Zitieren
APA
Sakares, W., Udomnilobol, U., Pan, X., Yampayon, K., Ekwattanakit, S., Viprakasit, V., Limwongse, C., Srichairatanakool, S., Teerawonganan, P., Kunsa-Ngiem, S., Khaowroongrueng, V., Techatanawat, I., Prueksaritanont, T., & Yodsurang, V. (2025). Bridging Pharmacokinetics and Pharmacodynamics: A PBPK / PD Model‐Based Approach for Deferasirox Dosing in Transfusion‐Dependent Thalassemia. Clinical and Translational Science. https://doi.org/10.1111/cts.70355
Vancouver
Sakares W, Udomnilobol U, Pan X, Yampayon K, Ekwattanakit S, Viprakasit V, et al. Bridging Pharmacokinetics and Pharmacodynamics: A PBPK / PD Model‐Based Approach for Deferasirox Dosing in Transfusion‐Dependent Thalassemia. Clinical and Translational Science. 2025. doi:10.1111/cts.70355
BibTeX
@article{Sakares2025,
author = {Sakares, Watchara and Udomnilobol, Udomsak and Pan, Xian and Yampayon, Kittika and Ekwattanakit, Supachai and Viprakasit, Vip and Limwongse, Chanin and Srichairatanakool, Somdet and Teerawonganan, Polsak and Kunsa-Ngiem, Sumate and Khaowroongrueng, Vipada and Techatanawat, Isariya and Prueksaritanont, Thomayant and Yodsurang, Varalee},
title = {Bridging Pharmacokinetics and Pharmacodynamics: A PBPK / PD Model‐Based Approach for Deferasirox Dosing in Transfusion‐Dependent Thalassemia},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70355}
}
EUVIMED